Other Cancer Therapies

Biological therapy has emerged as an important fourth accepted method as a result of gains made in understanding the immune defenses against cancer. Progress in biotechnology has provided necessary quantities of biochemical molecules to support this therapy.

Since the progression of tumours requires the development of capillaries (a process known as angiogenesis) that supply tumour cells with oxygen and nutrients, interfering with this essential step is a promising therapeutic approach. Antiangiogenic drugs have been shown in animal studies to shrink tumours by destroying the capillaries that surround them and by preventing the production of new vessels. In combination with conventional therapy, they might be useful in the treatment of cancer. They remain an object of intensive research.

Tumour-associated antigens are present on tumour cells, but they also are found on the surface of normal cells; in addition, these antigens are not specific to a certain type of tumour but are seen in a variety of cancers. Despite the lack of tumour specificity, some tumour-associated antigens can serve as targets for attack by components of the immune system. For instance, antibodies can be produced that recognize a specific tumour antigen, and these antibodies can be linked to a variety of compounds — such as chemotherapeutic drugs and radioactive isotopes — that damage cancer cells. In this way the antibody serves as a sort of ''magic bullet'' that delivers the therapeutic agent directly to the tumour cell. In other cases a chemotherapeutic agent attached to an antibody destroys cancer cells by interacting with receptors on their surfaces that trigger apoptosis.

Another immunologic approach to treating cancer is the so-called tumour vaccine. The object of a cancer vaccine is to stimulate components of the immune system, such as T cells, to recognize, attack, and destroy cancer cells. Tumour vaccines have been created by using a number of different substances, including tumour antigens and inactivated cancer cells.

Tumour-associated antigens also can be used as tumour markers. Because elevated levels of tumour-associated antigens indicate that the presence of a tumour is likely, they remain a useful tool either in screening for the recurrence of previously treated cancers or in preventive screening. For example, prostate-specific antigen (PSA) is used to screen for carcinoma of the prostate.

Other biological response modifiers that have been developed include interferon, tumour necrosis factor, and various interleukins. Interleukin-2, for example, stimulates the growth of a wide range of antigen-fighting cells, including several kinds that can kill cancer cells.

Knowledge about the genetic defects that lead to cancer suggests that cancer can be treated by fixing these altered genes. One strategy is to replace a defective gene with its normal counterpart, using methods of recombinant DNA technology. Researchers are exploring methods that can insert genes into tumour cells.